Teva Pharmaceutical Industries (TEVA) Return on Capital Employed (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Return on Capital Employed came in at 6.6% in Q2 2026, up 333.0% YoY from 1.52% in Q2 2025, and down 22.59% on a QoQ basis from 8.52% in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Return on Capital Employed (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Return on Capital Employed data on file, last reported at 6.6% in Q2 2026.
- Quarterly Return on Capital Employed rose 333.0% year-over-year to 6.6% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 6.6% (up 333.0% YoY) and the FY2025 annual result came in at 8.11%, up 917.0% from the prior year.
- Return on Capital Employed fell to 6.6% in Q2 2026, from 8.52% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 8.52% in Q1 2026 to a low of 6.72% in Q4 2022.
- A 5-year average of 0.92% and a median of 1.49% in 2023 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 1042 bps in 2022, down 1140 bps in 2022.
- Tracing TEVA's Return on Capital Employed over 5 years: stood at 6.72% in 2022, then surged by 121 bps to 1.42% in 2023, then plunged by 177 bps to 1.09% in 2024, then soared by 835 bps to 8.03% in 2025, then decreased by 18 bps to 6.6% in 2026.
- The last three Return on Capital Employed figures came in at 6.6% (Q2 2026), 8.52% (Q1 2026), and 8.03% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 3.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.60% |
| Mar 31, 2026 | 8.52% |
| Dec 31, 2025 | 8.03% |
| Sep 30, 2025 | 6.41% |
| Jun 30, 2025 | 3.26% |
| Mar 31, 2025 | 1.57% |
| Dec 31, 2024 | -1.09% |
| Sep 30, 2024 | 1.74% |
| Jun 30, 2024 | 3.02% |
| Mar 31, 2024 | 0.78% |
| Dec 31, 2023 | 1.42% |
| Sep 30, 2023 | -4.05% |
| Jun 30, 2023 | -3.76% |
| Mar 31, 2023 | -4.49% |
| Dec 31, 2022 | -6.72% |
| Sep 30, 2022 | -3.51% |
| Jun 30, 2022 | -2.76% |
| Mar 31, 2022 | 1.59% |
| Dec 31, 2021 | 4.67% |
| Sep 30, 2021 | 5.57% |